Last reviewed · How we verify

NCT04243564

Laryngeal Mask in Morbid Obesity

Withdrawn NA Last updated 5 December 2023
What this trial tests

NA trial testing Supraglottic device (SGD) in Morbid Obesity. Withdrawn.

Timeline
15 February 2021
Primary endpoint
15 March 2022
15 June 2022

Quick facts

Lead sponsorUniversity of Padova
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposediagnostic
Start date15 February 2021
Primary completion15 March 2022
Estimated completion15 June 2022
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Padova

Who can join

Adults 18 to 65, any sex, with Morbid Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators study the performance of both masks, Proseal Laryngeal Mask Airway (PLMA) and I-gel, as temporary ventilatory supraglottic airway devices (SGDs) before tracheal intubation in morbidly obese patients. Data are lacking in such population of patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Morbid Obesity

Currently open trials in the same condition.

Other University of Padova trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04243564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing